Protective effects of telmisartan on heart problems due to medicine (doxorubicin) in patients with breast cancer
Phase 4
- Conditions
- Health Condition 1: C50- Malignant neoplasm of breast
- Registration Number
- CTRI/2019/05/019245
- Lead Sponsor
- ICMR
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients with breast cancer
Having taken doxorubicin treatment
Exclusion Criteria
Baseline LVEF <50% or NYHA class II-IV.
History of heart failure, cardiomyopathy or myocardial infarction.
Serum creatinine >=2.5 mg/dl or estimated GFR <30 ml/min/1.73m2
Known allergy, hypersensitivity or contraindication to any drugs to ACE I or ARBs.
Prior chest radiation or chemotherapy.
Deranged LFTs like bilirubin >1.5mg/dl and enzymes 2 to 3 times elevated above upper limit of normal.
Pregnancy or breastfeeding.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in global longitudinal strain on myocardial strain imaging using echocardiogram from baseline to completion of the studyTimepoint: 6 months
- Secondary Outcome Measures
Name Time Method Distance covered in 6-minute walk testTimepoint: 6 months